Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status
1990

Tumor Markers CA 19-9 and CA-50 in Pancreatic Cancer

Sample size: 89 publication Evidence: moderate

Author Information

Author(s): P. Masson, B. Palsson, A. Andren-Sandberg

Primary Institution: University Hospital, Lund, Sweden

Hypothesis

Can the tumor markers CA 19-9 and CA-50 differentiate pancreatic cancer in patients with different Lewis blood group statuses?

Conclusion

The study found that CA 19-9 and CA-50 levels can indicate the presence of pancreatic cancer, even in patients with the Lewis phenotype Le (a - b -).

Supporting Evidence

  • CA 19-9 and CA-50 levels were similar in patients with pancreatic cancer regardless of their Lewis blood group status.
  • Significant differences in tumor marker levels were found between cancer patients and those without cancer.
  • High correlation between CA 19-9 and CA-50 levels was observed in pancreatic cancer patients.

Takeaway

Doctors can use certain blood tests to help find out if someone has pancreatic cancer, even if their blood type is unusual.

Methodology

Blood samples were collected from patients suspected of having pancreatic cancer, and tumor markers were analyzed using specific kits.

Limitations

The study's patient sample size was limited, which may affect the generalizability of the findings.

Participant Demographics

Patients included 67 with confirmed pancreatic cancer and 22 without cancer, with a focus on Lewis blood group status.

Statistical Information

P-Value

0.019 for Le (a - b -) frequency comparison

Statistical Significance

p=0.005 for CA 19-9 and 0.035 for CA-50

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication